NRX Pharmaceuticals' (NRXP) HOPE Therapeutics subsidiary said Monday it has signed a non-binding agreement for $30 million in debt financing for its first interventional psychiatric clinics using the drug ketamine.
The company also signed a non-binding agreement for $10 million worth of financing for five existing clinics in the western US.
The company said it has been offered enough financing to build a network of clinics in the US, the UK and France that could generate annual revenue of more than $100 million.
Price: 2.0500, Change: -0.04, Percent Change: -1.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments